BeiGene, Ltd.
Anti-PD1 antibodies and their use as therapeutics and diagnostics
Last updated:
Abstract:
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Status:
Grant
Type:
Utility
Filling date:
14 May 2018
Issue date:
31 Dec 2019